NCT06268327
Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Jan 2024); last known: Not Yet Recruiting
- Study First Submitted
- Minor: routine updates
Endpoints
Primary
Adding adjuvant cisplatin and gemcitabine versus capecitabine in triple-negative Breast cancer patients with non pathologically complete response after neoadjuvant standard chemotherapy
Timeframe: 2 years
Secondary (1)
Comparison of patients who receive cisplatin and gemcitabine versus capecitabine in Triple negative breast cancer
Arms and interventions
cisplatin and gemicitabineExperimental
patients with triple negative breast cancer will recieve adjuvant cisplatin and gemicitabine in non pathological complete response after neo-adjuvant standard chemotherapy with dose of cisplatin 70mg/m2 at day one and gemicitabine 1000mg/m2 day one and day eight every 21 day for six cycle
capecitabineExperimental
patients with triple negative breast cancer will recieve adjuvant capecitabin in non pathological complete response after neo-adjuvant standard chemotherapy with dose of capecitabine 1000-1250 mg/m2 every 21 day for six cycle
Drugs: Cisplatin injection and gemcitabine, Capecitabine tablets